The rapid and aggressive spread of artemisinin-resistant Plasmodium falciparum carrying the kelch13
Introduction
The global adoption of artemisinin-based combination treatments (ACTs), consisting of an artemisinin derivative and a partner drug, has played a key role in the worldwide reduction of malaria cases and deaths. 1 In the last decade, however, Plasmodium falciparum parasites with decreased sensitivity to artemisinin have emerged at multiple locations in the Greater Mekong Sub-Region (GMS). [2] [3] [4] These resistant parasites exhibit a reduced clearing rate during treatment, 2, 5, 6 such that treatment efficacy relies more heavily on the partner drug. As a result, resistance to the partner drug may emerge, as has recently been the case with the partner drug piperaquine, leading to ACT treatment failures. 4, 7 In the GMS, slow artemisinin clearance rates have been associated with genetic mutations in two domains of the parasite's kelch13 gene. 8 Numerous independently arising kelch13 mutations have been found in GMS resistant parasites, [9] [10] [11] and several of these mutations have been validated in relation with clinical and in vitro artemisinin resistance. 12 Increasingly, the genotyping of kelch13 is being used for the surveillance of artemisinin resistance. 5, [9] [10] [11] After an initial period in which many kelch13 resistant alleles circulated concurrently, diversity has declined dramatically in the eastern part of the GMS (comprising Cambodia, northeast Thailand, southern Laos and Vietnam) where the C580Y allele has become the most prevalent, replacing other circulating mutations. 13 Although the spread of C580Y may have been underpinned by the concurrence of a piperaquine-resistant haplotype, 14 this allele has also been found in western Thailand 6 and in Guyana, 15 suggesting it may be highly beneficial to resistant parasites.
Ancestry reconstruction of the PNG kelch13 C580Y genomes
The pronounced similarity between the C580Y mutants and parasites from Timika suggest a genetic contribution from the Indonesian population, although C580Y mutations have not been reported in Indonesian Papua. One possibility is that the Wewak mutants originate from a geographically intermediate location, and they are the result of long-term continuous recombination between Indonesian and PNG populations. A different hypothesis is that the mutants have acquired through recombination, and retained, portions of genomes circulating in Indonesian Papua which provide some selective advantage. The first scenario would result in a random distribution of shared alleles, while the second would likely produce a limited number of long shared haplotypes.
To evaluate these hypotheses, we performed a genome-wide estimation of identity by descent (IBD) between each pair of samples. IBD models recombination processes, comparing genotype sequences to identify genome regions that are likely be identical because of common ancestry rather than by chance. We estimated the proportion of IBD between the PNG-C580Y-1 genome and those in the comparison populations using hmmIBD, and plotted its distribution (Supplementary Figure 5A ). No IDB with Cambodian parasites was detected, further supporting a local origin of the PNG C580Y. This was confirmed by a genome-wide IDB network using isoRelate, which showed large clusters of haplotype sharing in Cambodia and Indonesia, but no relationship to the Wewak mutants (Supplementary Figure 6 ). The mutants shared lower IBD with parasites from PNG sites (<2%) than is typically observed among local parasites, suggesting they did not originate at the PNG sites analyzed (Supplementary Figure 5B ). However, they shared considerably higher IBD proportions with Indonesian population (~3.5-5.5%), suggesting that substantial portions of their genome shares its origin with parasites circulating in Timika. To determine how these portions are distributed across the PNG-C580Y-1 genome, we mapped the IDB predictions for each comparator population (Supplementary Figure 6 ). Some genome regions were IBD with populations in both PNG and Indonesia, indicating island-wide shared haplotypes. We also identified several loci, notably in chromosomes 5, 10 and 13, where long haplotypes were identical to those in Indonesia, and not found elsewhere in PNG (Supplementary Table 6 ). The size of these haplotypes suggests they were recently acquired from a donor population-putatively, one circulating in Indonesian Papua-and are possibly under evolutionary selection, raising the question of a possible relation to the C580Y mutation.
Genetic variants association with kelch13 C580Y
If IBD shared segments were acquired from Indonesian parasites because they contain beneficial alleles, we would expect them to contain variants that circulate in Indonesian Papua but are rare in PNG. We estimated the FST differentiation measure to identify non-synonymous SNPs where the allele carried by Wewak C580Y mutants is common in the Indonesian samples (FST <0.2 between Timika and the mutants), but not in PNG (mean FST ≥ 0.5 between Timika and all PNG sites). These stringent criteria identified 34 SNPs, of which 25 are located in four of the nine IBD regions shared with Indonesia ( Table 2) .
The selected SNPs are highly enriched for variants implicated in drug response, or located in genes associated with drug resistance. IBD region #3 on chromosome 5 contains mutations Y184F and N1042D in the mdr1 gene, which has been implicated in resistance to multiple antimalarials 29, 30 including artemisinin; the Y184F variant is common in the GMS, where it has been under selection. 31 In IBD region #9 on chromosome 13, we found ferredoxin D193Y, a component of the genetic background associated with artemisinin resistance in the GMS. 24 In IBD region #6 on chromosome 10, we found three noteworthy hits: the T38I mutation in the autophagy-related protein 18 gene (atg18), associated with artemisinin response and widespread in SE Asia; and two SNPs (N280S and 659S) in the NLI interacting factor-like phosphatase (nif4), implicated in conjunction with atg18. 32 We also observed a number of drug-related hits outside the predicted IBD regions, such as Q225H in the purine nucleoside phosphorylase gene (pnp) on chromosome 5, which circulates in the GMS and has been associated with drug resistance. 33 Also on chromosome 5, the K753Q mutation in the amino acid transporter PF3D7_0515500 has been implicated in artemether response. 34 Finally, we found G248R in gene PF3D7_1450800, associated to artemisinin resistance in a large-scale analysis. 24 IDB networks around specific loci confirmed that, although Wewak mutants possess haplotypes around kelch13 that are distinct from those in both Cambodia and Indonesia, they clearly cluster with the Timika population at other genes related to drug resistance, such as atg18, mdr1 and pnp ( Supplementary Figures 8, 9 ).
Discussion
Over several decades, the spread of drug resistance from the GMS has rendered multiple drugs ineffective in Africa, at the cost of hundreds of thousands of lives. Therefore, the current rise of artemisinin resistance in southeast Asia is an urgent concern, since fast-acting artemisinin combination therapies are the preferred frontline treatments in nearly all endemic countries. The GMS is not the only region with the conditions for the development of drug resistance: historically, resistance to multiple drugs, such as chloroquine 35 and sulfadoxine, 36 has emerged independently on the island of New Guinea, and therefore new resistant strains could develop there.
In this study, we identified three infections from parasites carrying the kelch13 C580Y mutation, the most widespread artemisinin resistant allele. C580Y has rapidly overtaken other kelch13 variants, becoming dominant in large parts of the GMS, 13 and was confirmed by a transfection study to confer resistance in vitro. 37 The discovery of three C580Y mutants in Wewak, almost identical at genomic level, raises multiple important questions. First, are these parasites actually resistant to artemisinin? Second, were these mutants imported into PNG as a result of the recent aggressive spread of C580Y in the GMS, or are they parasites native to New Guinea that have acquired the mutation either through independent emergence, or through recombination with Asian mutants? Third, do these mutants represent a confined local phenomenon, or are they representatives of a spreading population across the island, perhaps across national borders? Fourth, if the C580Y mutations were not imported, did they result from an isolated "chance event", or from a gradual evolutionary process that selected a genetic background to boost fitness? The results presented here provide convincing evidence to answer all these questions.
Although clinical parasite clearance rates were not measured in this study, in vitro tests clearly showed that the Wewak mutants are resistant to artemisinin in their ring stage, consistent with C580Y mutants elsewhere. Since no failures occurred in patients infected with these parasites after artemether-lumefantrine treatment, there is no reason to suspect that this ACT is no longer efficacious, and the clinical significance of the C580Y allele in New Guinea needs to be clarified by in vivo efficacy studies. However, parasite populations stand to benefit from decreased sensitivity even without treatment failures: slower clearance increases drug exposure, boosting the parasites' chances to develop further resistance. Recent research in the GMS showed that continued drug exposure leads to accumulation of mutations that confer higher levels of resistance, facilitating the spread of multidrug resistant lineages. 13 We found no evidence that the C580Y mutations found in Wewak have been imported from the GMS. At whole-genome level, the mutants appear more similar to New Guinean parasites than to Cambodian ones, and analyses of flanking haplotypes and IBD showed no evidence that the C580Y mutations were acquired from imported parasites. Overall, there is a strong case for an independent emergence of the C580Y mutation on the island of New Guinea, although our data is insufficient to pinpoint a precise geographic origin. At genome-wide level, the Wewak C580Y mutants are substantially different from the majority of our PNG samples, with relatively low IBD, suggesting they originated outside the sampled sites. The relatively high level of IBD shared with the Timika population raises the possibility that the C580Y mutants could have crossed the border from Indonesia, or that they may be the product of interbreeding between the two countries. In all cases, the marked differences distinguishing these mutants from previous East Sepik parasites suggests they belong to a spreading population, whose bounds within the island are presently unknown.
The sharing of long haplotypes between the mutants and the Timika parasites are strongly suggestive of a process of selection. If the Indonesian population's genetic contribution were governed by longterm interbreeding, IBD shared fragments would be short, due to breakdown from multiple recombination events. Instead, we observed long shared segments in specific parts of the genome, consistent with recently acquisition and rapid propagation, characteristic of recent selection. 38 This hypothesis is bolstered by the large number of alleles associated with resistance to artemisinin and related drugs shared by the C580Y mutants and the Indonesian Papua parasites, several of which are located in the IBD fragments, and absent from other PNG samples. In an IBD shared segment, we found the ferredoxin D193Y mutation, which strongly correlates with artemisinin resistance variants in the GMS, 24 and is otherwise absent from PNG. The drug resistant allele mdr1 Y184F, known to be under selection in the GMS, 31 is also present in a shared IBD segment, with another less common mdr1 mutation, N1042D. mdr1 is a transporter contributing to the efflux of toxic substances from the parasite's food vacuole, and its polymorphisms have been associated with resistance to multiple drugs. Another IBD segment, on chromosome 10, harbours the atg18 T38I variant, associated with decreased sensitivities to dihydroartemisinin and artemether (the artemisinin derivative used in PNG) in the China-Myanmar border area, 32 and two non-synonymous changes in the nearby nif4 gene; other mutations in nif4 were previously associated with artemisinin sensitivity in two independent genome-wide association studies in Southeast Asia. 24, 32 Additional variants related to artemisinin response, present in Indonesian Papua but rare in PNG, were found in the Wewak C580Y mutants, outside the predicted IBD segments. One of these mutations (PF3D7_0515500 K753Q) is in a transporter that has been associated with response to artemether in African parasites. 34 Another mutation in a nucleoside phosphorylase (pnp Q225H), recently shown to affect response to quinine and mefloquine, 33 two drugs related to lumefantrine, the partner drug used in PNG. Such a high number of mutations implicated in drug response is unlikely to have resulted by chance; it is more plausible that these variants have been acquired and selected for their contribution to a resistant phenotype. Therefore, we propose that the Wewak C580Y lineage has accumulated a complex genetic background through multiple recombination events and selection under artemisinin drug pressure, and that the kelch13 C580Y mutation is a component of a complex constellation of genetic changes, rather than a standalone mutation generated by a chance event.
The findings presented are of great concern for public health, both locally and globally. They provide evidence of a population of ART-R parasites spreading within New Guinea has acquired a complex genetic background, complete with the kelch13 C580Y allele, which provides a survival advantage under artemisinin drug pressure. Such pressure may have intensified due to decreasing P. falciparum transmission across the island as a result of control interventions. 39 These parasites are a potential danger to the efficacy of ACTs in New Guinea and could constitute a threat if they are not contained. Genetic data from New Guinea is currently sparse and insufficient to adequately demarcate the spread of this population, which may be present on both sides of the Indonesia-PNG border. Public health authorities in PNG and collaborating research institutions are currently ramping up genetic monitoring of malaria parasites at sentinel sites, and we hope this will provide much needed detailed data to map artemisinin resistant parasites and help develop containment strategies.
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Oyola SO, Ariani CV, Hamilton Table 3 . Non-synonymous mutations shared by Wewak C580Y mutants and the Indonesian Papua population. For each position, we show (left to right): the chromosome and nucleotide position; the frequency in the Wewak C580Y mutants, and at each of the sites surveyed; the id and name of the gene; the amino acid substitution; and, if the mutation is found in a shared IBD region (orange background), the id of the region (see Supplementary Table 6 ). Mutations associated with antimalarial drug resistance in published studies (see main text) are listed in bold type. Table 7 
Supplementary Methods

Description of sampling locations
Wewak district comprises about 20,000 inhabitants, nearly all village-dwellers along the coast and inland. Free distribution of long-lasting insecticidal mosquito nets (LLIN) was implemented by The Government of PNG between 2005 and 2009 and between 2009 and 2013. 1 Average LLIN usage was 55% in 2008 and 2009 and 32.9-67.7% in 2013-2014. 2,3 P. falciparum entomological inoculation rates in Dreikikir, about 50 km from our study area, dropped from 159 infective bites/person/year in 2008 to 53 in 2011, following LLIN distribution. 4 Current first-line regime is Artemether plus Lumefantrine, officially introduced in 2010. Free distribution of ACT and rapid diagnostic tests (RDT) was initiated by the malaria control programme in 2012. 1 Previously, intramuscularly artemether was sometimes used in patients who failed first-line treatment regime.
Determinations of kelch13 flanking haplotypes
Determinations of flanking haplotypes using microsatellites and selected SNPs. We genotyped kelch13 flanking microsatellite loci and single-nucleotide polymorphisms (SNPs) located at -33.9 kb, -8.1 kb, -5.02 kb, -1.91 kb, 4.1 kb, 9.33 kb, 15.82 kb, and 43.85 kb from the kelch13 gene (negative and positive values denote upstream and downstream distance from kelch13, respectively) by direct sequence as previously described 5, 6 . We also genotyped four KEL1/PLA1 marker SNPs located at -137.5 kb, -14.06 kb, 6.97 kb, and 24.91 kb 7 . At positions -137.5 kb and 24.91 kb, SNPs were determined by direct sequencing of PCR products. At position 6.97 kb, SNP-specific amplification was performed with HiDi DNA polymerase (myPOLS Biotec, Konstanz, Germany). At position -14.06 kb, SNP was detected by combination of Derived Cleaved Amplified Polymorphic Sequences (dCAPS) assay and PstI digestion. These analyses produced genotypes for 18 polymorphic sites, since multiple polymorphisms were identified at positions -8.1 kb (TAT repeat and one SNP site), -5.02 kb (TAAAA, TAAA and TA repeats and one SNP site), -1.91 kb (TAA and TA repeats), 9.33 kb (TAAA and TA repeats). Primers used for these analyses were shown in Supplementary Table 7 .
Determinations of flanking haplotypes using whole-genome sequencing data. Comparing flanking haplotypes constructed by concatenating WGS genotypes at SNPs with minor allele frequency (MAF) >=0.01 in a region of 300kbp centered at kelch13 ( Supplementary Figure 4 , Supplementary Methods).
Comparison and ranking of kelch13 flanking haplotypes.
To assess flanking haplotypes, we assigned for each sample a score based on the extent of haplotype sequence identity with the consensus haplotype of the Wewak kelch13 mutants. To obtain a score for the upstream (left-hand) flank, we started from the position nearest to the core locus (the kelch13 gene), and counted the number of consecutive positions (ignoring missing/heterozygous positons) in the upstream direction that carried an allele identical to that in the C580Y mutants, until a mismatch was found. The score for the downstream (right-hand) flank is determined in the same way, by traversing in the downstream direction from the end of kelch13. The final score for the sample was obtained by adding the scores for the two flanks.
Genotyping of background mutations associated with artemisinin resistance
Genotyping of background alleles associated with artemisinin resistance (D193Y in fd, T484I in mdr2, V127M in arps10, I356T in crt, V1157L in nif4 and C1484F in pibp) 8 were performed by multiplex PCR and probe qPCR as previously described. 9 Copy number variants of plasmepsin 2 and multidrug resistance gene 1 genes were determined using published procedures. 10 Four artemisinin-resistant clones (MRA-1236, MRA-1238, MRA-1240 and MRA-1241) and three isolates obtained in Cambodia 11 were used as comparators.
Supplementary Tables
Supplementary Table 1 -Genotypes at loci of resistance for ACT component drugs. Supplementary Table 4 -Amino acid alleles at loci in the artemisinin resistance genetic background.
The table includes positions previously associated with kelch13 mutations in the GMS (see main text). Coloured background denoted alleles different from the reference (wild type). Light blue background reflects a mutant allele different from that previously reported in the GMS. 
Supplementary Figures
Supplementary Figure 1 -Approximate locations of residence of patients infected with kelch13 C580Y mutant parasites.
This map of Wewak town shows the place of abode of the three patients whose parasites carried the kelch13 C580Y allele (red markers), the distance between these locations (blue lines), and the location of the two clinics where the study was carried out (green markers)
Supplementary Figure 2 -RSA survival rates of Wewak parasites.
The plot compares the RSA survival rate (see Methods) of one of the Wewak kelch13 C580Y mutants (left, red marker) against those for wild-type parasites from the same area (right, black markers). RSA survival rates could not be determined for the remaining two Wewak kelch13 C580Y mutants. Artemisinin-susceptible laboratory clone 3D7 showed no parasite at 700 nmol/L. MRA-1236 and MRA-1240 (artemisinin-resistant laboratory clones) showed survival rates 14.3% and 27.0%, respectively.
Supplementary Figure 3 -Sampling sites in New Guinea for parasites used in wholegenome analyses. Sites that contributed samples in both countries that form part of the island of New Guinea (Indonesia to the west and PNG to the east) are shown by coloured circular markers. The column on the left shows the sample identifier, while the columns on the right show the matching score and the kelch13 allele carried by the sample.
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